214 related articles for article (PubMed ID: 8172439)
1. Prophylaxis for opportunistic infections in patients with HIV infection.
Gallant JE; Moore RD; Chaisson RE
Ann Intern Med; 1994 Jun; 120(11):932-44. PubMed ID: 8172439
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
Torres RA; Barr M; Thorn M; Gregory G; Kiely S; Chanin E; Carlo C; Martin M; Thornton J
Am J Med; 1993 Dec; 95(6):573-83. PubMed ID: 8018144
[TBL] [Abstract][Full Text] [Related]
3. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.
Girard PM; Landman R; Gaudebout C; Olivares R; Saimot AG; Jelazko P; Gaudebout C; Certain A; Boué F; Bouvet E
N Engl J Med; 1993 May; 328(21):1514-20. PubMed ID: 8479488
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
Bucher HC; Griffith L; Guyatt GH; Opravil M
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Jun; 15(2):104-14. PubMed ID: 9241108
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of preventing AIDS-related opportunistic infections.
Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
[TBL] [Abstract][Full Text] [Related]
6. Natural history of opportunistic disease in an HIV-infected urban clinical cohort.
Moore RD; Chaisson RE
Ann Intern Med; 1996 Apr; 124(7):633-42. PubMed ID: 8607591
[TBL] [Abstract][Full Text] [Related]
7. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV.
Podzamczer D; Salazar A; Jiménez J; Consiglio E; Santín M; Casanova A; Rufí G; Gudiol F
Ann Intern Med; 1995 May; 122(10):755-61. PubMed ID: 7717598
[TBL] [Abstract][Full Text] [Related]
8. Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world.
Kaplan JE; Hu DJ; Holmes KK; Jaffe HW; Masur H; De Cock KM
Am J Trop Med Hyg; 1996 Jul; 55(1):1-11. PubMed ID: 8702012
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis of opportunistic infections in persons with HIV infection.
Stearn BF; Polis MA
Cleve Clin J Med; 1994; 61(3):187-94. PubMed ID: 7913002
[TBL] [Abstract][Full Text] [Related]
10. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients.
Opravil M; Hirschel B; Lazzarin A; Heald A; Pechère M; Rüttimann S; Iten A; von Overbeck J; Oertle D; Praz G
Clin Infect Dis; 1995 Mar; 20(3):531-41. PubMed ID: 7756472
[TBL] [Abstract][Full Text] [Related]
11. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine.
Mallolas J; Zamora L; Gatell JM; Miró JM; Vernet E; Valls ME; Soriano E; SanMiguel JG
AIDS; 1993 Jan; 7(1):59-64. PubMed ID: 8442918
[TBL] [Abstract][Full Text] [Related]
12. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
Warnock AC; Rimland D
Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
[TBL] [Abstract][Full Text] [Related]
13. A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS.
Payen MC; De Wit S; Sommereijns B; Clumeck N
Biomed Pharmacother; 1997; 51(10):439-45. PubMed ID: 9863502
[TBL] [Abstract][Full Text] [Related]
14. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.
Hoover DR; Saah AJ; Bacellar H; Phair J; Detels R; Anderson R; Kaslow RA
N Engl J Med; 1993 Dec; 329(26):1922-6. PubMed ID: 7902536
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.
Bozzette SA; Finkelstein DM; Spector SA; Frame P; Powderly WG; He W; Phillips L; Craven D; van der Horst C; Feinberg J
N Engl J Med; 1995 Mar; 332(11):693-9. PubMed ID: 7854375
[TBL] [Abstract][Full Text] [Related]
16. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group.
Schneider MM; Hoepelman AI; Eeftinck Schattenkerk JK; Nielsen TL; van der Graaf Y; Frissen JP; van der Ende IM; Kolsters AF; Borleffs JC
N Engl J Med; 1992 Dec; 327(26):1836-41. PubMed ID: 1360145
[TBL] [Abstract][Full Text] [Related]
17. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
Chaisson RE; Keruly J; Richman DD; Moore RD
Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
[TBL] [Abstract][Full Text] [Related]
18. Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus.
Richards FO; Kovacs JA; Luft BJ
Clin Infect Dis; 1995 Aug; 21 Suppl 1():S49-56. PubMed ID: 8547512
[TBL] [Abstract][Full Text] [Related]
19. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021.
Hardy WD; Feinberg J; Finkelstein DM; Power ME; He W; Kaczka C; Frame PT; Holmes M; Waskin H; Fass RJ
N Engl J Med; 1992 Dec; 327(26):1842-8. PubMed ID: 1448121
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
